A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations

Trial Profile

A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Aug 2017

At a glance

  • Drugs Dasatinib (Primary) ; Clofarabine; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Folinic acid; Folinic acid; Mercaptopurine; Methotrexate; Pegaspargase; Prednisone; Prednisone; Tioguanine; Vincristine
  • Indications Acute lymphoblastic leukaemia; Brain metastases; Leukaemia; Testicular cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top